Imagene AI delivers precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, response prediction, and companion diagnostic development. From H&E-based molecular profiling to AI-IHC companion diagnostics, Imagene AI develops AI-powered pathology assays that translate biological insight into patient selection and diagnostic strategies.LungOI®, the first AI-based NSCLC multi-gene biomarker panel to receive a PLA code and CMS payment rate, was developed, validated, and deployed across multiple centers and laboratories globally.
We collaborate with leading biopharma organizations to advance biomarker-driven programs from discovery through clinical development and deployment.
We are committed to advancing precision medicine and expanding its impact across cancer and beyond. If you are passionate about applying AI to meaningful challenges in oncology and helping shape the future of Precision Oncology and cancer care, we invite you to join us.
